TAKEDA PHARMACEUTIC-SP ADR (TAK) Forecast, Price Target & Analyst Ratings

NYSE:TAK • US8740602052

Current stock price

16.635 USD
-0.01 (-0.09%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TAKEDA PHARMACEUTIC-SP ADR (TAK).

Forecast Snapshot

Consensus Price Target

Price Target
$20.07
+ 20.67% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 13, 2026
Period
Q4 / 2026
EPS Estimate
-¥12
Revenue Estimate
1.134T
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
74.74%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$20.07
Upside
+ 20.67%
From current price of $16.64 to mean target of $20.07, Based on 19 analyst forecasts
Low
$16.06
Median
$20.11
High
$26.04

Price Target Revisions

1 Month
10.43%
3 Months
21.52%

Price Target Summary

19 Wall Street analysts provided a forecast for the next 12 months for TAK. The average price target is 20.07 USD. This implies a price increase of 20.67% is expected in the next year compared to the current price of 16.635.
The average price target has been revised upward by 21.52% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

TAK Current Analyst RatingTAK Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6

Analyst Ratings History

TAK Historical Analyst RatingsTAK Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15 20

Analyst Ratings Consensus

ChartMill Buy Consensus
74.74%
TAK was analyzed by 19 analysts. The buy percentage consensus is at 75. So analysts seem to be have mildly positive about TAK.
In the previous month the buy percentage consensus was at a similar level.
TAK was analyzed by 19 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2023-05-16TD CowenMaintains Outperform -> Outperform
2023-04-04TD CowenMaintains Outperform
2023-03-16B of A SecuritiesUpgrade Neutral -> Buy
2022-07-19Cowen & Co.Upgrade Market Perform -> Outperform
2021-10-07Morgan StanleyDowngrade Overweight -> Equal-Weight

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 13, 2026
Period
Q4 / 2026
EPS Estimate
-¥12
Revenue Estimate
1.134T
Revenue Q2Q
7.69%
EPS Q2Q
62.88%
Number of Analysts
5

Next Earnings Revisions

Revenue (1 Month)
0.22%
Revenue (3 Months)
3.20%
EPS (1 Month)
-1.09%
EPS (3 Months)
-26.93%

Next Earnings Summary

TAK is expected to report earnings on 5/13/2026. The consensus EPS estimate for the next earnings is -12.12 USD and the consensus revenue estimate is 1.13T USD.
The next earnings revenue estimate has been revised upward by 3.2% in the past 3 months.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2028

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028
Revenue
YoY % growth
TAK revenue by date.TAK revenue by date.
4.027T
12.85%		4.264T
5.87%		4.582T
7.45%		4.589T
0.16%		4.645T
1.22%		4.705T
1.29%
EBITDA
YoY % growth
TAK ebitda by date.TAK ebitda by date.
1.215T
7.68%		1.159T
-4.65%		1.316T
13.58%		1.239T
-5.83%		1.235T
-0.38%		1.286T
4.13%
EBIT
YoY % growth
TAK ebit by date.TAK ebit by date.
550.895B
0.99%		430.787B
-21.80%		554.704B
28.77%		401.98B
-27.53%		503.99B
25.38%		N/A
Operating Margin
TAK operating margin by date.TAK operating margin by date.
13.68%10.10%12.11%8.76%10.85%N/A
EPS
YoY % growth
TAK eps by date.TAK eps by date.
102.16
38.81%		46.02
-54.95%		34.16
-25.77%		60.49
77.07%		89.80
48.46%		103.09
14.79%

All data in JPY

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q4 / 26 Q1 / 27 Q1 / 28
EPS
Q2Q % growth		-12.12
62.88%		53.50
34.84%		54.81
2.45%
Revenue
Q2Q % growth		1.134T
7.69%		1.127T
1.85%		1.155T
2.51%
EBITDA
Q2Q % growth		236.987B
-67.88%		N/AN/A
EBIT
Q2Q % growth		N/AN/AN/A

All data in JPY

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

TAK Yearly Revenue VS EstimatesTAK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1T 2T 3T 4T
TAK Yearly EPS VS EstimatesTAK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 50 -50 100

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
44.51%
EPS Next 5 Year
N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
0.47%
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
77.92%
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

TAKEDA PHARMACEUTIC-SP ADR / TAK Forecast FAQ

What is the price target for TAK stock?

19 analysts have analysed TAK and the average price target is 20.07 USD. This implies a price increase of 20.67% is expected in the next year compared to the current price of 16.635.

What is the next earnings date for TAK stock?

TAKEDA PHARMACEUTIC-SP ADR (TAK) will report earnings on 2026-05-13, before the market open.

What are the consensus estimates for TAKEDA PHARMACEUTIC-SP ADR (TAK) next earnings?

The consensus EPS estimate for the next earnings of TAKEDA PHARMACEUTIC-SP ADR (TAK) is -12.12 USD and the consensus revenue estimate is 1.13T USD.

Can you provide the expected long term growth rate for TAKEDA PHARMACEUTIC-SP ADR stock?

The expected long term growth rate for TAKEDA PHARMACEUTIC-SP ADR (TAK) is 0.47%.